Program
Cetirizine
Also written as “Cetirizine (Zyrtec)”, “AC-170 0.24%” and “Ceterizine”.
Its studies are mostly in Rhinitis, Allergic, Seasonal · Hypersensitivity · Urticaria · Conjunctivitis, Allergic · Rhinitis, Allergic, led by 12 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Aciex Therapeutics | 70 open or running | phase 3since Apr 7, 2011 | Apr 7, 2011 | none ahead |
| GlaxoSmithKline | 50 open or running | phase 4since Aug 1, 2013 | Jun 19, 2007 | none ahead |
| JDP Therapeutics | 30 open or running | phase 3since Dec 18, 2013 | Dec 18, 2013 | none ahead |
| Johnson & Johnson | 30 open or running | phase 4since Sep 30, 2016 | Mar 23, 2011 | none ahead |
| Dr. Reddy's Laboratories | 20 open or running | phase 1since Feb 4, 2010 | Feb 4, 2010 | none ahead |
| Novartis | 20 open or running | phase 1since Apr 13, 2009 | Apr 13, 2009 | none ahead |
| Sun Pharmaceutical Industries | 20 open or running | no phasesince Oct 17, 2008 | Oct 17, 2008 | none ahead |
| Teva Pharmaceutical Industries | 20 open or running | phase 1since Mar 17, 2009 | Mar 17, 2009 | none ahead |
| Viatris | 20 open or running | phase 1since Mar 30, 2008 | Mar 30, 2008 | none ahead |
| Lunan Pharmaceutical Group | 11 open or running | phase 3since Feb 6, 2025 | Feb 6, 2025 | none ahead |
| nicox-ophthalmics-inc | 10 open or running | phase 3since Apr 20, 2016 | Apr 20, 2016 | none ahead |
| tersera-therapeutics-llc | 10 open or running | phase 2since Dec 3, 2019 | Dec 3, 2019 | none ahead |
Also a collaborator on its studies: algorithme-pharma-inc, ORA, Pfizer and ohm-laboratories-inc.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 17 studies since Jun 19, 2007.
- Mar 8, 2012Phase 3 study in Conjunctivitis, AllergicAciex Therapeutics · NCT01551056 · 91 enrolled · United States
- Sep 12, 2012Phase 3 study in Conjunctivitis, AllergicAciex Therapeutics · NCT01685242 · 100 enrolled · United States
- Jun 17, 2013Phase 3 study in Conjunctivitis, AllergicAciex Therapeutics · NCT01881113 · 101 enrolled · United States
- Aug 1, 2013Phase 4 study in RhinitisGlaxoSmithKline · NCT01916226 · 682 enrolled · United States
- Dec 18, 2013JDP Therapeutics's first study: phase 1 study in Acute UrticariaNew to JDP TherapeuticsJDP Therapeutics · NCT02024152 · 24 enrolled · Canada
- Dec 18, 2013Phase 3 study in UrticariaJDP Therapeutics · NCT02023164 · 36 enrolled · United States, Canada
- Apr 29, 2014Phase 3 study in Atopic Disease (Including Allergic Conjunctivitis)Aciex Therapeutics · NCT02132169 · 512 enrolled · United States
- Jun 13, 2014Phase 1 study in HealthyAciex Therapeutics · NCT02173249 · 11 enrolled · United States
- Apr 20, 2016nicox-ophthalmics-inc's first study: phase 3 study in Healthy SubjectsNew to nicox-ophthalmics-incnicox-ophthalmics-inc · NCT02756624 · 516 enrolled · United States
- Sep 30, 2016Phase 4 study in Rhinitis, AllergicJohnson & Johnson · NCT02932774 · 683 enrolled
- Oct 14, 2016Phase 3 study in Acute UrticariaJDP Therapeutics · NCT02935699 · 262 enrolled · United States, Canada
- Dec 10, 2018Phase 1 study in HypersensitivityJohnson & Johnson · NCT03772158 · 40 enrolled · Canada
- Dec 3, 2019tersera-therapeutics-llc's first study: phase 2 study in Oncology Patients Receiving ChemotherapyNew to tersera-therapeutics-llctersera-therapeutics-llc · NCT04189588 · 34 enrolled · United States
- Feb 6, 2025Lunan Pharmaceutical Group's first study: phase 3 study in Acute UrticariaNew to Lunan Pharmaceutical GroupLunan Pharmaceutical Group · NCT06819774 · 284 planned · China
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 31 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT06819774Acute Urticaria · China | 3 | Recruiting | Lunan Pharmaceutical Group | Aug 2025 | 284 |
| NCT04189588Oncology Patients Receiving Chemotherapy · United States | 2 | Completed | tersera-therapeutics-llc | Nov 23, 2020 | 34 |
| NCT03772158Hypersensitivity · Canada | 1 | Completed | Johnson & Johnson | Feb 3, 2019 | 40 |
| NCT02935699Acute Urticaria · United States, Canada | 3 | Completed | JDP Therapeutics | Apr 30, 2018 | 262 |
| NCT02932774Rhinitis, Allergic | 4 | Completed | Johnson & Johnson | Jul 2001 | 683 |
| NCT02756624Healthy Subjects · United States | 3 | Completed | nicox-ophthalmics-inc | Aug 2016 | 516 |
| NCT02173249Healthy · United States | 1 | Completed | Aciex Therapeutics | Aug 2014 | 11 |
| NCT02132169Atopic Disease (Including Allergic Conjunctivitis) · United States | 3 | Completed | Aciex Therapeutics | Oct 2014 | 512 |
| NCT02024152Acute Urticaria · Canada | 1 | Completed | JDP Therapeutics | Jul 2011 | 24 |
| NCT02023164Urticaria · United States, Canada | 3 | Completed | JDP Therapeutics | Dec 2014 | 36 |
| NCT01916226Rhinitis · United States | 4 | Completed | GlaxoSmithKline | Oct 1, 2013 | 682 |
| NCT01881113Conjunctivitis, Allergic · United States | 3 | Completed | Aciex Therapeutics | Oct 2013 | 101 |
| NCT01685242Conjunctivitis, Allergic · United States | 3 | Completed | Aciex Therapeutics | Nov 2012 | 100 |
| NCT01551056Conjunctivitis, Allergic · United States | 3 | Completed | Aciex Therapeutics | Jun 2012 | 91 |
| NCT01495338Normal Ocular Health · United States | 1 | Completed | Aciex Therapeutics | Dec 2011 | 60 |
| NCT02447393Dermatitis · Japan | 1 | Completed | GlaxoSmithKline | Apr 30, 2008 | 20 |
| NCT01332188Conjunctivitis, Allergic · United States | 3 | Completed | Aciex Therapeutics | Jun 2011 | 101 |
| NCT01322282Hypersensitivity · Canada | 1 | Completed | Johnson & Johnson | Mar 2011 | 36 |
| NCT01064115Healthy | 1 | Completed | Dr. Reddy's Laboratories | Jan 2006 | 30 |
| NCT01064102Healthy | 1 | Completed | Dr. Reddy's Laboratories | Jan 2006 | 30 |
| NCT00972504Rhinitis, Allergic, Seasonal · Germany | 2 | Completed | GlaxoSmithKline | Aug 1, 2009 | 54 |
| NCT00881634Hypersensitivity | 1 | Completed | Novartis | Jul 2005 | 40 |
| NCT00881127Hypersensitivity | 1 | Completed | Novartis | Jul 2005 | 40 |
| NCT00864279Healthy · United States | 1 | Completed | Teva Pharmaceutical Industries | Sep 2006 | 26 |
| NCT00863902Healthy · United States | 1 | Completed | Teva Pharmaceutical Industries | Sep 2006 | 26 |
| NCT00851344Rhinitis, Allergic, Seasonal · Germany | 2 | Completed | GlaxoSmithKline | Nov 2008 | 54 |
| NCT00776139Healthy · United States | – | Completed | Sun Pharmaceutical Industries | Oct 2004 | 32 |
| NCT00776022Healthy · United States | – | Completed | Sun Pharmaceutical Industries | Apr 2005 | 32 |
| NCT00650065Healthy · United States | 1 | Completed | Viatris | Dec 2002 | 26 |
| NCT00649857Healthy · United States | 1 | Completed | Viatris | Dec 2002 | 18 |
| NCT00490204Rhinitis, Allergic, Perennial · Japan | 3 | Completed | GlaxoSmithKline | Oct 3, 2007 | 239 |
How it is read
Names in the registry
- “Cetirizine”, 6 entries
- “Cetirizine (Zyrtec)”, 5 entries
- “AC-170 0.24%”, 5 entries
- “Ceterizine”, 2 entries
- “cetirizine”, 2 entries
Codes read as this program: JDP205.
Conditions, from the studies’ own filings
- Rhinitis, Allergic, Seasonal, 8 studies
- Hypersensitivity, 6 studies
- Urticaria, 5 studies
- Conjunctivitis, Allergic, 5 studies
- Rhinitis, Allergic, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.